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Transforming growth factor betaFgf and Tgfβ are key regulators of bone development. It is not known, however, whether there is a
relationship between defective Fgf signalling, resulting in a premature cranial suture fusion, and Tgfβ
signalling. We used mouse calvaria osteoblasts carrying a mutation (hFGFR2-C278F) associated with
Crouzon and Pfeiffer syndromes to investigate effects of this mutation on cell growth and possible
mechanisms underlying it. Mutated osteoblasts displayed reduced S-phase, increased apoptosis and
increased differentiation. As Tgfβ signalling appeared to be required in an autocrine/paracrine manner for
osteoblast proliferation, we tested the hypothesis that reduced growth might be due, at least in part, to an
altered balance between FGF and Tgfβ signalling. Tgfβ expression was indeed decreased in mutated
osteoblasts, as compared to osteoblasts carrying the wild type hFGFR2. Treatment with Tgfβ, however,
neither increased proliferation in mutated osteoblasts, unlike in controls, nor rescued proliferation in control
osteoblasts treated with an Erk1/2 inhibitor. Signiﬁcantly, Erk2, that is important for proliferation, was
reduced relatively to Erk1 in mutated cells. Altogether this study suggests that the hFGFR2-C278F mutation
affects the osteoblast ability to respond to Tgfβ stimulation via the Erk pathway and that the overall effect of
the mutation is a loss of function.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Osteoblast growth and maturation is a complex process and
several signalling pathways are involved in its modulation and in
maintaining the balance between proliferation and differentiation
during bone development. Among key regulators of bone develop-
ment are ﬁbroblast growth factors (FGFs) and their tyrosine kinase
receptors (FGFRs) [1]. Upon FGF binding, dimerisation and trans-
phosphorylation of the receptor result in the activation of a number of
signal transduction pathways including Ras/MAPK (mitogen activat-
ed protein kinase), phosphoinositol-3 kinase (PI3-K), and phospho-
lipase C gamma (PLC-γ) [2,3].
Much interest in Fgf signalling in cranial bone development over
the last few years has stemmed from the discovery that single point
mutations in FGFRs represent the most common genetic cause of
craniosynostosis, that is premature fusion of cranial sutures [1,4-6].
Nonetheless, the mechanisms underlying these defects are not yet
fully understood.
FGFR1-3 are expressed in the developing cranial bone in charac-
teristic patterns [7-9]. Mutations in regions involved in ligand binding
and kinase activity, thought to cause a gain-of-function, have been
identiﬁed in all of these receptors and linked to syndromic craniosy-x: +44 020 7831 4366.
tics and Physiology, Faculty of
ll rights reserved.nostosis, such as Crouzon, Pfeiffer or Apert syndromes, but the most
commonly mutated receptor in patients with syndromic craniosynos-
tosis is FGFR2 [1,10]. Several Fgfs have been implicated in cranial bone
development [1,11]. In vitro and in vivo studies using a variety of
models have shown diverse effects of Fgf on bone growth and
differentiation and indicated that changes in the level of Fgf signalling,
either due to availability of ligands or functionality of the receptor, can
shift the balance between proliferation and skeletogenic differentia-
tion both in neural crest cells and in mesenchymal cells, the two
lineages from which the cranial vault osteoblasts are derived [11-20].
Besides Fgf, several other growth factors, includingmembers of the
transforming growth factor beta (Tgfβ) super-family, are known to
play key roles in bone growth and differentiation, and their role
depends on the stage of osteoblast maturation [2,21-23]. Of the three
mammalian Tgfβ isoforms, Tgfβ1 displays the highest levels of
expression in bone and most consistently induces osteoblast
proliferation [24-27]. The formation of a Tgf-TβRII (Tgfβ receptor
type 2) homodimer complex initiates Tgfβ signalling by promoting
further binding and activation of Tgfβ receptor type 1 (TβRI, ALK5) to
this complex. While Smads are key transducers of Tgfβ signalling,
other signalling pathways, such as MAPK, can be activated by Tgfβ
[28]. The MAPK (mitogen-activated protein kinase) pathway required
in osteoblast proliferation appears to be Erk1/2 (extracellular related
kinase), rather than JNK and p38 [29,30].
Cross-talking between Fgf and Tgfβ signalling has been suggested.
For example, it has been shown that Fgf2 signalling may control Tgfβ1
expression, and that Fgf2 and Tgfβ1 might regulate each other [31].
In addition, a mutation in TβRI has been described to cause
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carrying a mutated FGFR often display limited growth and increased
differentiation [33-37] and we wished to test the hypothesis that this
might be due, at least in part, to an altered balance between Fgf
signalling and other signalling pathways. Given the known effects of
Tgfβ on bone development and of cross-talk with Fgf signalling [31,38-
40], we focused our attention on this pathway.
The osteoblastic cell lineMC3T3, originated frommouse calvarium,
and more recently MC3T3 carrying mutated receptors, have been
widely used as amodel for studying bone development and osteoblast
differentiation [36,41,42]. One of themutations found in childrenwith
Crouzon or Pfeifer type of craniosynostosis is the mutation at position
278 (C278F) in the third immunoglobulin-like extracellular domain
IIIa of FGFR2 [5]. MC3T3 cells carrying FGFR2-C278F have been shown
to be a goodmodel of craniosynostotic cells, and, like osteoblasts from
patients with craniosynostosis, require longer time than controls to
reach conﬂuence [36]. Therefore we have used stable MC3T3 cell lines
carrying humanwild type FGFR2 (WT-FGFR2) or FGFR2-C278F [36] to
investigate the effect of this mutation on osteoblast behaviour and on
Tgfβ signalling, and to assess how Fgf and Tgfβ pathways may
interact.
Our analysis of FGFR2-C278F cells shows changes in their cell cycle
and reduced survival as compared to control MC3T3 and WT-FGFR2
cells, and that reduced growth appears to be due to altered Erk
signalling. We also show that in the mutated osteoblasts Tgfβ
expression is reduced, and that there is a reduction in Tgfβ-induced
proliferation mediated by Erk, suggesting convergence of Fgf and Tgfβ
signalling on Erk to induce proliferation.
2. Materials and methods
2.1. Cell culture
The osteoblastic cell lineMC3T3 and previously establishedMC3T3
cell lines stably transfected with either human FGFR2 (FGFR2-WT) or
FGFR2-C278F (FGFR2-C278F) [36] were cultured in α-MEM medium
(Gibco-BRL, Paisley, UK) containing 10% fetal bovine serum (FBS),
penicillin and streptomycin (100 U/ml; Gibco-BRL). Cultures were
passaged every 3 days and plated at a density of 20 000 cells/cm2.
Cells were allowed to attach for 3 h before treatment with the
following compounds that were used at the concentrations indicated
in Results: SU5402 (572630, Calbiochem), rhTGFβ1 (240-B-010, R&D
Systems), SB431542 (S4317, Sigma) and U0126 (9903, Cell Signalling
Technology). Cells were grown on 12 well culture plates for FACS
(Fluorescence activated cell sorting) analysis to monitor the cell cycle,
and on coverslips for immunoﬂuorescence. Live cells in culture were
viewed under an inverted light microscope (Axiovert 135M, Zeiss),
and photographed using a Hamamatsu ORCA-ER camera, visualised
using Volocity® software (Improvision).
2.2. Assessment of cell growth
Cell growth analysis was carried out in 96 well plates using the
methylene blue dye as previously reported [43]. Cells were ﬁxed in 4 %
paraformaldehyde (PFA) for 30 min before incubating with methy-
lene blue (1% w/v methylene blue (Gurr®) in 0.01 M borate buffer
(pH 8.5). After 4 washes with 0.01 M borate buffer (pH 8.5) to remove
excess dye, the intracellular methylene blue was extracted using 50%
v/v ethanol in 0.1 M HCl. The 96 well culture plate was stirred and
absorbance was measured at 650 nm (A650) in a microplate reader
(Revelation v4.21, Dynex Technologies, Inc).
2.3. Cell cycle and apoptosis analysis
Cells were detached by incubationwith Trypsin-EDTA (Invitrogen)
for 5 min, then pelleted and either resuspended in permeabilisingsolution (0.1% sodium citrate and 0.1% Triton X-100 in dH2O) for cell
cycle analysis or PBS (phosphate buffer saline) for measuring
apoptosis. Cells were kept on ice for up to 2 h before analysis. The
DNA was intercalated with 20 μl of 0.1 mg/ml 7 aminoactinomycin D
(7AAD) just prior to ﬂow cytometry analysis (Epics XL, Beckman
Coulter). Absorption of the 488 nm argon laser by 7AAD, resulted in
emission in FL3 (peaked at 647 nm), which was detected at 675 nm
with a band pass ﬁlter and the data recorded, using the EXPO32
software (Beckman Coulter). Gating was used for doublet discrimi-
nation. For cell cycle analysis, the frequency versus area of 7AAD was
plotted, resulting in a curve, which was mathematically analysed
using MultiCycle for Windows (Phoenix ﬂow systems, San Diego).
This resulted in the G0/G1, S and G2/M phase curves, and the
proportion of cells in each phase was determined by the Dean and Jett
method [44]. In the apoptosis study, 7AAD ﬂuorescence was plotted
against frequency and the 7AAD positive cells gated from the baseline
ﬂuorescence, highlighting the level of apoptosis based on increased
membrane permeability.
2.4. Phospho-histone H3 (pH3) immunocytochemistry
Mitotic cells cultured on coverslips were detected by incubating
with rabbit polyclonal anti-phospho-histone H3 (pH3) antibody
(Upstate Cell signaling solutions) dissolved in PBS containing 0.1%
bovine serum albumin and 0.5% Triton X-100 at 4 °C overnight and
washed using PBS. Samples where then incubated with anti-rabbit
immunoglobulins-FITC conjugated secondary antibodies (Dakocyto-
mation) dissolved in the same solution as the primary antibody, using
Hoescht 33258 (Molecular probes) as a counterstain. Coverslips were
mounted with Citiﬂuor™. Cells were imaged with a ProgRes® C14
(Jenoptik) camera mounted onto a Zeiss Axiophot 2 microscope using
the Openlab software (Improvision). pH3-positive cells and total
number of cells per coverslip were counted and mitotic cells
expressed as a percentage of the total cell number.
2.5. Protein extraction and Western blot
Protein extraction from cell pellets was performed with 50–200 μl
ice-cold lysis buffer (150 mMNaCl, 1% Nonidet P-40, 0.1% SDS, 50 mM
Tris–HCl pH 8.0) containing 1:25 proteinase inhibitor (Complete™,
Roche) and 1 mM Sodium Orthovanadate. Equal amounts of protein
(20–40 μg/lane) were separated by 12% SDS-PAGE. Membranes were
blocked in Tris-buffered saline containing 5% non-fat dry milk and
0.1% Tween-20 (TBST) and incubated with either anti-Erk1/2
(1:1000) or anti-pErk1/2 (1:2000) antibodies (9102, 9106, Cell
Signaling) at 4 °C overnight followed by washes with TBST. Bound
antibodies were detected either by horseradish peroxidase (HRP)-
conjugated rabbit anti-mouse (1:1000) or HRP-conjugated goat anti-
mouse secondary antibodies (P0260, P0447, Dakocytomation). The
enhanced chemiluminescence (ECL) method was used for immuno-
detection and densitometry was performed using Labimage (v2.7.1,
Kapelan). The Erk1 bands were normalised to Erk2 for relative
quantiﬁcation of Erk1/Erk2 ratios.
2.6. RNA extraction and reverse transcription
RNA extraction was carried out using the TRI®-Reagent (Sigma)
protocol. RNA was diluted to 1 ng/μl in a 10 μl volume of 2 μl of 10 pM
random hexamer (pN6, Roche) in DEPC (diethylpyrocarbonate)
water. Annealing was carried out at 70 °C for 10 min, followed by
5 min at 4 °C in a PTC-100 thermal cycler (MJ Research Inc.). Four μl of
RT buffer (2 μl of 10 mM dNTPs, 1 μl RNAsin, 1 μl reverse transcriptase
MMLV (Promega) in DEPC water) were then added to the annealed
solution. Reverse transcription and MMLV denaturing were per-
formed at 42 °C for 1 h and at 95 °C for 10 min, respectively.
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TaqMan® Fast Universal Master Mix (2X) with No AmpErase®
UNG (Applied Biosystems) was added to cDNA. Taqman® Gene
Expression assays (Applied Biosystems) used for measuring Tgfβ1
(Mm00441724_m1), Tgfβ2 (Mm004366952_m1) and Tgfβ3
(Mm00436960_m1), and normalised to Eukaryotic 18S rRNA (Part
no: 4352930E). Ampliﬁcation and analysis were performed using an
ABI 7500 FAST real time PCR machine.
2.8. Statistical analysis
All experiments were carried out at least in triplicate (n≥3) and
repeated at least three times. Data are expressed as mean±standard
error of the mean (M±SEM) and statistical differences between
FGFR2-C278F cells and each control assessed by ANOVA and
independent t-test using SPSS (version 14, SPSS Inc.); pb0.05 was
taken to indicate a signiﬁcant difference.
3. Results
3.1. Effects of FGFR2-C278F on proliferation and apoptosis
An initial analysis of FGFR2-C278F osteoblasts indicated that these
cells needed longer time in culture to reach conﬂuence than MC3T3
and FGFR2-WT cells, which for simplicity of presentation will be
referred to as “controls.” Therefore we investigated whether this was
due to a defect in proliferative capability, increased apoptosis, or both.
To conﬁrm that Fgf signalling is one of the pathways involved in cell
proliferation in all the cell lines used in this study, we assessed the
effect of the FGFR inhibitor SU5402 on cell growth, and found that
SU5402 reduced cell growth in all cell lines (Fig. 1). Further analysis of
the three cell lines showed a reduced increase in cell number over
time in FGFR2-C278F cells as compared to controls (Fig. 2A). In order
to investigate which phase of the cell cycle may be affected in the
mutated cells we carried out FACS analysis in 2-day cultures (Fig. 2).
The cell cycle proﬁle of MC3T3 and FGFR2-WT was comparable,
whereas the percentage of FGFR2-C278F cells in S phase was
signiﬁcantly lower, and that of cells in G2/M phase higher as
compared to controls (Fig. 2B). As the FACS analysis carried out did
not distinguish between cells in G2 and M phase, staining with pH3
antibody both on coverslips (Fig. 2C) and in suspension (not shown)
followed by FACS analysis was used to assess changes in M phase.
Analysis of mitosis detected by pH3 showed that the percentage ofFig. 1. Effect of FGFR inhibitor SU5402 onMC3T3, R2-WT and R2-C278F osteoblast growth. Ce
cell growth was assessed by themethylene blue assay. Cell growth in treated groups is expres
a dose-dependent manner (n=3, ⁎pb0.05).cells in M phase was signiﬁcantly lower in FGFR2-C278F than in
control cell lines.
To assess whether apoptosis may also contribute to the lower cell
number observed in FGFR2-C278F cells, TUNEL (not shown) and FACS
analysis (Fig. 3) was carried out in 2-day cultures. Though at this time-
point the extent of apoptosis was small in all cultures, the percentage
of apoptotic cells in FGFR2-C278F cultures was signiﬁcantly higher
than in both control cell lines (Fig. 3A). This difference greatly
increased with time in culture as indicated by FACS analysis at 7 days
(Fig. 3B).
We also assessed cell morphology in the three cell lines at 2 and
4 days in culture (Fig. 4). A signiﬁcant decrease in the percentage cells
with elongated/ﬁbroblastic morphology was observed in FGFR2-
C278F cultures at 2 days, as conﬁrmed by quantitative analysis (Fig.
4A–C, G). At 4 days in culture (Fig. 4D–F), themorphology of nearly all
cells in culture was cuboidal, but FGFR2-C278F cells, unlike controls,
were not fully conﬂuent.
3.2. Control of proliferation by Tgfβ signalling
In order to assess a possible autocrine role of Tgfβ signalling in the
proliferation of our cell lines, Tgfβ receptor was inhibited using
different concentrations of SB431542, a TβRI inhibitor of ALK4, -5 and
-7 [45,46], and changes in cell growth measured (Fig. 5). Partial
inhibition of growth was induced in a dose-dependent manner in the
two control cell lines (Fig. 5). SB431542 also inhibited growth of
FGFR2-C278F cells, but maximal effect was already observed at the
lower dose tested (Fig. 5), suggesting that Tgfβ signalling is less active
in these cells. To further investigate changes in Tgfβ signalling caused
by the FGFR2 mutation, we assessed expression of Tgfβ1, Tgfβ2, and
Tgfβ3 mRNA in all cell lines (Fig. 6). They all expressed Tgfβ1 and
Tgfβ3, and, though at very low levels, also Tgfβ2. In the FGFR2-
C278F cells, however, Tgfβ1 and Tgfβ3 levels of expression were
signiﬁcantly lower than in the control lines (Fig. 6A–C). We therefore
investigated whether exogenous Tgfβ1 could increase the prolifera-
tive activity of mutated osteoblasts (Fig. 7). Whereas Tgfβ1 did
increase proliferation in the control cell lines, no signiﬁcant difference
was observed in FGFR2-C278F cells. This suggested that defective Fgf
signalling in the mutated cells impaired Tgfβ signalling modulating
proliferation.
3.3. Role of Erk in Fgf and Tgfβ signalling
As Fgf is known to mediate osteoblast proliferation via the Erk1/2
pathway we investigated Erk1/2 protein expression in the threells were treated with no SU5402 (CTRL), 5 μMor 10 μMSU5402 every 24 h for 3 days and
sed as percentage of growth in untreated controls. SU5402 treatment reduces growth in
Fig. 2. Changes in cell growth and cell cycle inMC3T3, R2-WT and R2-C278F osteoblasts.
(A) Curves show osteoblast growth evaluated by counting viable cells at the indicated
times. Cell growth is slower in R2-C278F cells than in controls. Error bars in (A) are the
standard deviation. (B) Bar charts show the percentage of 7AAD stained cells in G0/1, S
and G2/M phases of cell cycle as assessed by FACS analysis at 2 days in culture. Both S-
phase (decreased) and G2/M phase (increased) are signiﬁcantly affected in R2-C278F
compared to controls. (n≥4, ⁎pb0.05 Mann–Whitney U test). (C) Analysis of the
percentage of mitotic cells in M-phase as assessed by phosphorylated histone 3 (pH3)
immunocytochemistry. The percentage of R2-C278F cells in M-Phase is signiﬁcantly
lower than in controls (n=3, ⁎pb0.05).
Fig. 3. Changes in cell survival analyzed by FACS. Bar charts show the percentage of cell
death and apoptosis measured by DNA intercalation with 7AAD at 2 days (A) and 7 days
(B) in culture. Cell survival is lower in R2-C278F cells compared to both controls and
R2-WT cells (n=3, ⁎pb0.05).
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showed that Erk1/2 was signiﬁcantly higher in FGFR2-C278F cells
than in controls (Fig. 8A). The relative levels of Erk1 and Erk2 were
further analyzed by Western blot and densitometric analysis in cells
cultured for 2 and 4 days (Fig. 8B–D). At both time points the ratio
between Erk1 and Erk2 was higher in the mutated cells than in
controls. Furthermore, analysis of phosphorylated Erk also showed a
higher pErk1/pErk2 ratio in FGFR2-C278F cells (Fig. 8E). This
suggested that Erk signalling is affected in FGFR2-C278F cells andthat Tgfβ1 might be unable to stimulate proliferation of the mutated
cells because of defective Erk signalling.
To establish whether Tgfβ effect on proliferation was mediated via
Erk1/2, we assessed the effect on cell proliferation of the Erk1/2
inhibitor U0126, alone or in combination with Tgfβ1 (Fig. 9).
Treatment with U0126 signiﬁcantly reduced cell growth in FGFR2-
C278F cells compared to controls, both at 2 and 3 days in culture (Fig.
9A–B). We also assessed whether Tgfβ1 was able to rescue inhibition
of proliferation induced by U0126 in the MC3T3 control cells (Fig. 9C).
No signiﬁcant increase in proliferation was observed upon Tgfβ1
treatment, suggesting that Tgfβ-induced osteoblast proliferation is
mediated via Erk signalling.
4. Discussion
This study has identiﬁed novel mechanisms by which a single
point mutation in the human FGFR2 affects osteoblast behaviour and
their response to Tgfβ signalling.
4.1. FGFR2-C278F reduction in proliferation and survival is due to loss of
function
A critical defect that we have found inMC3T3 cells carrying FGFR2-
C278F concerns their decreased proliferation and survival. Reduced
growth in FGFR2-C278F cells appears to result from a reduction in the
number of cells entering S phase. The effect on proliferation observed
seems speciﬁcally due to the C278F mutation, as expression of the
normal human receptor in MC3T3 does not induce the same
phenotype and changes in the cell cycle. Furthermore, cells expressing
the mutated receptor behave in a fashion similar to that observed in
primary human craniosynostotic cells, that is reduced cell growth and
premature differentiation [36,47]. This supports the view that our
mutated cells are a good model to study the molecular basis of
craniosynostosis.
Fig. 4. Morphology of MC3T3, R2-WT and R2-C278F at 2 and 4 days in culture assessed by phase contrast microscopy. (A–C) Two-day cultures: cells with ﬁbroblastic morphology
(arrowheads) and cuboidal cells (white arrows) are present in MC3T3 cells. In R2-WT cultures most cells display a ﬁbroblastic morphology whereas in R2-C278F cultures most cells
are cuboidal and several bright round cells are present (wide arrow). (D–F) Four-day cultures: MC3T3 and R2-WT cultures are fully conﬂuent, whereas R2-C278F cultures are not.
Black circles indicate areas devoid of cells. (G) Bar chart shows quantiﬁcation of cells with ﬁbroblastic morphology in 2-day cultures. The percentage of cells with ﬁbroblastic
morphology is lower in R2-C278F cells than in control lines (n=3, ⁎pb0.05). Scale bar=50 μm.
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in the third immunoglobulin loop of the receptor (IgIIIa/IIIc domain)
that plays a role in receptor dimerisation and its consequentFig. 5. Reduction in proliferation by Tgf Reduction in proliferation by Tgfβ receptor inhibit
(CTRL), 1, 10 or 20 μMSB431542 every 24 h and cell growth assessed 3 days later bymethylen
R2-C278F but not in controls, and that this effect is not enhanced by increasing dose (n=3activation [48-50]. Mutations in the C278 (or C342) of FGFR2 lead
to covalent cross-linking of these cysteines and maintain the receptor
in a dimeric active form even in the absence of ligand. Though C278F ision in MC3T3, R2-WT and R2-C278F osteoblasts. Cells were treated with no SB431542
e blue assay. Note that 1 μMSB431542 is sufﬁcient to reduce cell growth signiﬁcantly in
, ⁎pb0.05 ANOVA).
Fig. 6. Tgfβ1 and -3 gene expression is signiﬁcantly reduced in cells carrying FGFR2-
C278F. Cells were cultured for 2 or 4 days before relative quantiﬁcation (RQ) of Tgfβ1, 2
and 3 expressions. (A) Tgfβ1 expression is signiﬁcantly lower in R2-C278F cells than in
controls at 2 and 4 days in culture. (B) Tgfβ2 expression is not signiﬁcantly different
between the three cell lines neither at 2 or 4 days. (C) Tgfβ3 expression is lower in R2-
C278F cells than in both controls at 2 and 4 days (n =3, ⁎pb0.05).
Fig. 7. TGFβ1 does not rescue proliferation in R2-C278F cells. Three hours after plating,
cells were treated with 10 ng/ml Tgfβ1 every 24 h for 2 or 3 days and analysed for cell
growth by methylene blue assay. (A–B) The treated groups in both MC3T3 and R2-WT
cells show increased cell growth, whereas there is no difference between treated and
untreated groups in R2-C278F cells (n=3, ⁎pb0.05).
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developing cranial bone is osteoblast proliferation, our results suggest
that the net effect of the mutation is a loss rather than a gain offunction. This is consistent with a previous report showing rapid
cellular degradation of FGFR2-C278F [42].
Furthermore, the mutated cells undergo apoptosis to a larger
extent than controls. This is also consistent with a loss of FGFR2
function, as Fgf signalling is known to play a role in osteoblast
proliferation and survival [51]. The effects of the C278F mutation on
cell death parallel those reported in a study where FGFR2-C342Y
(Crouzon syndrome) was introduced in OB1 cells, a cell line derived
by immortalizing primary newbornmouse calvarium osteoblasts with
polyoma large T antigen [49]. Also human osteoblasts from Apert
patients carrying the FGFR2-S252W mutation display increased
apoptosis [52], though the mechanism underlying it may be different,
as the effect of that mutation appears to be loss of ligand speciﬁcity
and/or extension of ligand–receptor interaction rather than consti-
tutive activation of the receptor [53].
The effects of the C278F mutation on proliferation might seem
superﬁcially rather different from those reported in C342Y-OB1 cells,
as it was suggested that the C342Y OB1 cells do not display a decrease
in proliferation [49]. However, in that study the basal growth activity
of the control and mutated cells was not directly compared under
normal culture conditions. In low serum, a proliferative response to
FGF1 was observed in OB1 cells, whereas only a small increase in DNA
synthesis was induced by FGF1 in C342Y-OB1 cells [49]. This suggests
that in these cells, like in FGFR2-C278F cells, the ability to proliferate
may be reduced. Finally, our mutated FGFR2-C278F cells display
premature differentiation and increased mineralization as compared
to controls. This feature differs from the reduced mineralization
reported in C342Y-OB1 cells [49], but it is in agreement with increased
differentiation observed in primary cultures of osteoprogenitors from
craniosynostosis patients [36,47], as well as with increased differen-
tiation observed in FGFR2-S252W mutant cells obtained either from
Apert syndrome patients or by transfecting the mutated receptor into
C3H10T1/2 mouse mesenchymal cells [15,54].
Fig. 8. Erk1/Erk2 ratio is altered in mutated cells. (A) FACS analysis of Erk1/2 expression in 2-day cultures. The level of Erk1/2 is signiﬁcantly higher in R2-C278F cells than in R2-WT
andMC3T3 (approximately 1.5 fold). The data represent the M±SEM from 3 independent experiments, normalised to the MC3T3 control. (B) Cells were cultured for 2 or 4 days and
analysed for Erk1/Erk2, and phosphorylated-Erk1/Erk2 (pErk1/pErk1) protein expression by Western blotting. (C–E) Ratio of Erk1/Erk2 and pErk1/Erk2 expression assessed by
densitometric analysis of Western blots at 2 (C) and 4 (D–E) days and normalised to that of MC3T3 controls. The ratio of both total and phosphorylated Erk1/Erk2 is signiﬁcantly
higher in R2-C278F cells than in the two control cell lines (⁎pb0.05).
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FGFR2-C278F osteoblasts
Both expression of Tgfβ1 and the ability of this factor to stimulate
proliferation are reduced in FGFR2-C278F cells. This dependence of
Tgfβ on a functional FGFR2 is consistent with previous work
suggesting a complex and dynamic cross-talk between Fgf and Tgfβ
signalling during cranial bone development, starting from the neural
crest [39,55,56]. Inhibition of Tgfβ signalling in our cell lines resulted
in a decrease in cell proliferation, suggesting cell growth modulation
via an autocrine mechanism. Consistent with this proposition, Tgfβ
signalling is impaired in FGFR2-C278F cells, as indicated by the lower
concentration of Tgfβ receptor inhibitor required to reduce cell
growth in these cells as compared to controls and the decrease in both
Tgfβ1 and Tgfβ3 expression found in these cells. These two Tgfβ formsare highly expressed in non-fusing sutures in vivo [57,58], and their
down-regulation might contribute to premature suture fusion. We
focused our attention on TGFβ1 as it is the most abundant TGFβ in
bone, and TGFβ3 expression in MC3T3 was much lower than that of
Tgfβ1, suggesting a greater role for the latter. Furthermore, data from
a parallel study in our laboratory suggested that TGFβ3 mRNA
expression is regulated by Tgfβ1 in MC3T3 (Pungchanchaikul and
Ferretti, unpublished data).
The Erk pathway is an important mediator of proliferation in
MC3T3 cells, as inhibition of this pathway signiﬁcantly reduces cell
growth. Altered Erk1/2 expression and decreased proliferation is
observed in FGFR2-C278F (this study), whereas cells carrying the self-
activating FGFR2-S252W or FGFR2-WT activate the Erk1/2 pathway
and increase proliferation [54], further supporting the view that the
net effect of the C278F mutation is loss of receptor function. Altered
Fig. 9. Effect of Tgfβ1 and U0126 onMC3T3 cell proliferation. Cell growthwas measured
by methylene blue assay in cultures treated for 2 or 3 days of Erk1/2 inhibitor U0126
and/or Tgfβ1 at 24-h intervals. (A–B) Cells were grown for 2 (A) and 3 (B) days in the
presence of U0126 (n=3, ⁎pb0.05). (C) MC3T3 cells at 3 days treated with Tgfβ1 and
U0126 (n=3, ⁎pb0.05 ANOVA).
354 K.M.A. Lee et al. / Biochimica et Biophysica Acta 1802 (2010) 347–355Erk1/2 signalling in our FGFR2-C278F cells might be responsible for
their accumulation in G1 and G2 as it has been proposed that Erk1/2
controls G1/S and G2/M transitions [59,60]. Indeed, in serum-
stimulated ﬁbroblasts, both Erk1 and Erk2 are strongly phosphory-
lated in G1 phase, but only Erk2 is strongly phosphorylated in G2/M
phase [61].
Altered Erk1/2 signalling also appears to affect the ability of the
cells to respond to Tgfβ1 stimulation, indicating that a functional Erk
pathway is required for Tgfβ-induced osteoblast growth. In addition,endogenous Tgfβ, that we speculate is required for autocrine
signalling, is reduced in FGFR2-C278F cells. Therefore, both a decrease
in endogenous Tgfβ and impairment of the Erk1/2 signalling pathway
are likely to contribute to the decrease in cell growth observed in
mutated cells. Modulation of the levels of Erk by over-expressing Erk1
and Erk2, either wild type or mutated at their phosphorylation sites,
will be important to further clarify their role in proliferation and
differentiation of normal and craniosynostotic osteoblasts.
4.3. Conclusions
This work supports the view that osteoblast behaviour is regulated
by interaction between Fgf and Tgfβ signalling. Crucially, it suggests
that normal Erk signalling is required for Tgfβ induction of osteoblast
proliferation, and that this depends on a functional FGFR2 signalling.
Altogether these ﬁndings are consistent with the hypothesis that the
net effect of the FGFR2-C278F mutation is a loss of function.
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